|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
Capitalization1 |
153 304 | 198 695 | 231 557 | 210 954 | 210 954 | - |
Entreprise Value (EV)1 |
169 216 | 214 945 | 247 453 | 226 113 | 223 339 | 221 082 |
P/E ratio |
60,5x | 32,9x | 23,9x | 17,6x | 15,6x | 14,5x |
Yield |
3,34% | 2,60% | 2,48% | 2,94% | 3,13% | 3,41% |
Capitalization / Revenue |
3,82x | 4,70x | 4,94x | 4,38x | 4,08x | 3,88x |
EV / Revenue |
4,22x | 5,08x | 5,28x | 4,69x | 4,32x | 4,07x |
EV / EBITDA |
11,2x | 13,6x | 12,6x | 11,4x | 10,3x | 9,50x |
Price to Book |
4,42x | 7,42x | 9,00x | 6,94x | 6,27x | 5,49x |
Nbr of stocks (in thousands) |
2 724 437 | 2 600 377 | 2 545 984 | 2 530 034 | 2 530 034 | - |
Reference price (USD) |
56,3 | 76,4 | 91,0 | 83,4 | 83,4 | 83,4 |
Last update |
02/02/2018 | 02/01/2019 | 02/05/2020 | 12/21/2020 | 12/21/2020 | 12/21/2020 |
1 USD in Million Estimates
|
|
Income Statement Evolution | |
|
|
Annual Income Statement Data |
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
Net sales1 |
40 122 | 42 294 | 46 840 | 48 200 | 51 713 | 54 308 |
EBITDA1 |
15 131 | 15 781 | 19 572 | 19 887 | 21 734 | 23 268 |
Operating profit (EBIT)1 |
13 551 | 13 926 | 15 920 | 17 399 | 19 042 | 20 976 |
Operating Margin |
33,8% | 32,9% | 34,0% | 36,1% | 36,8% | 38,6% |
Pre-Tax Profit (EBT)1 |
6 747 | 8 701 | 11 464 | 14 782 | 17 391 | 17 933 |
Net income1 |
2 568 | 6 220 | 9 843 | 12 144 | 13 239 | 13 809 |
Net margin |
6,40% | 14,7% | 21,0% | 25,2% | 25,6% | 25,4% |
EPS2 |
0,93 | 2,32 | 3,81 | 4,74 | 5,36 | 5,77 |
Dividend per Share2 |
1,88 | 1,99 | 2,26 | 2,45 | 2,61 | 2,84 |
Last update |
02/02/2018 | 02/01/2019 | 02/05/2020 | 01/15/2021 | 01/15/2021 | 01/15/2021 |
1 USD in Million 2 USD Estimates
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
Net Debt1 |
15 912 | 16 250 | 15 896 | 15 159 | 12 384 | 10 127 |
Net Cash position1 |
- | - | - | - | - | - |
Leverage (Debt / EBITDA) |
1,05x | 1,03x | 0,81x | 0,76x | 0,57x | 0,44x |
Free Cash Flow1 |
4 559 | 8 307 | 9 967 | 12 335 | 14 965 | 16 248 |
ROE (Net Profit / Equities) |
29,4% | 38,1% | 50,9% | 52,7% | 49,6% | 49,6% |
Shareholders' equity1 |
8 741 | 16 335 | 19 348 | 23 063 | 26 688 | 27 827 |
ROA (Net Profit / Asset) |
11,9% | 13,6% | 11,8% | 15,8% | 16,4% | 18,2% |
Assets1 |
21 521 | 45 631 | 83 517 | 76 793 | 80 611 | 76 003 |
Book Value Per Share2 |
12,7 | 10,3 | 10,1 | 12,0 | 13,3 | 15,2 |
Cash Flow per Share2 |
2,35 | 4,08 | 5,21 | 5,81 | 7,91 | 7,39 |
Capex1 |
1 888 | 2 615 | 3 473 | 3 133 | 3 300 | 3 499 |
Capex / Sales |
4,71% | 6,18% | 7,41% | 6,50% | 6,38% | 6,44% |
Last update |
02/02/2018 | 02/01/2019 | 02/05/2020 | 01/07/2021 | 01/07/2021 | 01/04/2021 |
1 USD in Million 2 USD Estimates
|
|
|
| Financial data source © 2021 S&P Global Market Intelligence
|
|
|
Merck to move COVID-19 treatment into large trials, sees sales recovering this year |
|
MERCK AND COMPANY Leader in oncology, modest valuation |
Capitalization (USD) 210 954 271 357 Net sales (USD) 46 840 000 000 Number of employees 71 000 Sales / Employee (USD) 659 718 Free-Float capitalization (USD) 149 077 263 799 Avg. Exchange 20 sessions (USD) 846 096 541 Average Daily Capital Traded 0,40%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|